These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 16361627

  • 1. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors.
    Kondagunta GV, Bacik J, Bajorin D, Dobrzynski D, Sheinfeld J, Motzer RJ, Bosl GJ.
    J Clin Oncol; 2005 Dec 20; 23(36):9290-4. PubMed ID: 16361627
    [Abstract] [Full Text] [Related]

  • 2. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M, Miyake H, Hara I, Muramaki M, Takenaka A, Fujisawa M.
    Hinyokika Kiyo; 2007 Dec 20; 53(12):851-6. PubMed ID: 18203521
    [Abstract] [Full Text] [Related]

  • 3. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    Culine S, Kramar A, Théodore C, Geoffrois L, Chevreau C, Biron P, Nguyen BB, Héron JF, Kerbrat P, Caty A, Delva R, Fargeot P, Fizazi K, Bouzy J, Droz JP, Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    J Clin Oncol; 2008 Jan 20; 26(3):421-7. PubMed ID: 18202419
    [Abstract] [Full Text] [Related]

  • 4. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer.
    Rick O, Bokemeyer C, Weinknecht S, Schirren J, Pottek T, Hartmann JT, Braun T, Rachud B, Weissbach L, Hartmann M, Siegert W, Beyer J.
    J Clin Oncol; 2004 Sep 15; 22(18):3713-9. PubMed ID: 15365067
    [Abstract] [Full Text] [Related]

  • 5. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C, German Testicular Cancer Study Group.
    J Clin Oncol; 2003 Nov 15; 21(22):4083-91. PubMed ID: 14568987
    [Abstract] [Full Text] [Related]

  • 6. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
    Culine S, Theodore C, Terrier-Lacombe MJ, Droz JP.
    J Urol; 1997 Mar 15; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
    [Abstract] [Full Text] [Related]

  • 7. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
    Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, Horger M, Schleicher J, Derigs G, Mayer-Steinacker R, Beyer J, Kuczyk MA, Bokemeyer C, German Testicular Cancer Study Group.
    J Clin Oncol; 2007 Dec 20; 25(36):5742-7. PubMed ID: 18089869
    [Abstract] [Full Text] [Related]

  • 8. Chemotherapy for good-risk germ cell tumors: current concepts and controversies.
    Vaughn DJ.
    Urol Clin North Am; 2007 May 20; 34(2):171-7; abstract viii-ix. PubMed ID: 17484922
    [Abstract] [Full Text] [Related]

  • 9. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.
    Kondagunta GV, Sheinfeld J, Mazumdar M, Mariani TV, Bajorin D, Bacik J, Bosl GJ, Motzer RJ.
    J Clin Oncol; 2004 Feb 01; 22(3):464-7. PubMed ID: 14752068
    [Abstract] [Full Text] [Related]

  • 10. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH, Schefer H, Thalmann GN, Karamitopoulou-Diamantis E, Fey MF, Studer UE.
    J Urol; 2008 Jan 01; 179(1):163-6. PubMed ID: 18001800
    [Abstract] [Full Text] [Related]

  • 11. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
    Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, Rogers PC, Colombani P, Rescorla F, Billmire DF, Vinocur CD, Hawkins EP, Davis MM, Perlman EJ, London WB, Castleberry RP, Pediatric Oncology Group 9049, Children's Cancer Group 8882.
    J Clin Oncol; 2004 Jul 01; 22(13):2691-700. PubMed ID: 15226336
    [Abstract] [Full Text] [Related]

  • 12. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
    Grimison PS, Stockler MR, Thomson DB, Olver IN, Harvey VJ, Gebski VJ, Lewis CR, Levi JA, Boyer MJ, Gurney H, Craft P, Boland AL, Simes RJ, Toner GC.
    J Natl Cancer Inst; 2010 Aug 18; 102(16):1253-62. PubMed ID: 20631341
    [Abstract] [Full Text] [Related]

  • 13. Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin.
    Brada M, Horwich A, Peckham MJ.
    Cancer Treat Rep; 1987 Jun 18; 71(6):655-6. PubMed ID: 2438041
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study.
    Mardiak J, Sálek T, Sycová-Milá Z, Obertová J, Recková M, Mego M, Hlavatá Z, Brozmanová K, Risnyovzská Z, Svetlovská D, Koza I.
    Neoplasma; 2007 Jun 18; 54(3):240-5. PubMed ID: 17447857
    [Abstract] [Full Text] [Related]

  • 16. Management of good risk germ-cell tumours.
    Troost MM, Sternberg CN, de Wit R.
    BJU Int; 2009 Nov 18; 104(9 Pt B):1387-91. PubMed ID: 19840018
    [Abstract] [Full Text] [Related]

  • 17. Lowered Cisplatin Dose and No Bleomycin in the Treatment of Pediatric Germ Cell Tumors: Results of the GCT-99 Protocol From the Brazilian Germ Cell Pediatric Oncology Cooperative Group.
    Lopes LF, Macedo CR, Aguiar Sdos S, Barreto JH, Martins GE, Sonaglio V, Milone M, Lima ER, Almeida MT, Lopes PM, Watanabe FM, D'Andrea ML, Pianovski MA, Melaragno R, Vianna SM, Moreira ME, Bruniera P, de Oliveira CZ.
    J Clin Oncol; 2016 Feb 20; 34(6):603-10. PubMed ID: 26729441
    [Abstract] [Full Text] [Related]

  • 18. Drug dose delivery and treatment outcome relationship in standard bleomycin, etoposide and cisplatin combination chemotherapy in nonseminomatous germ cell tumor patients.
    Gutierrez-Delgado F, Titov DA, Tjulandin SA, Garin AM.
    Neoplasma; 1999 Feb 20; 46(3):190-5. PubMed ID: 10613596
    [Abstract] [Full Text] [Related]

  • 19. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.
    Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, Geller NL, Fair WR, Herr H, Sogani P.
    J Clin Oncol; 1993 Apr 20; 11(4):598-606. PubMed ID: 8386751
    [Abstract] [Full Text] [Related]

  • 20. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
    Hinton S, Catalano PJ, Einhorn LH, Nichols CR, David Crawford E, Vogelzang N, Trump D, Loehrer PJ.
    Cancer; 2003 Apr 15; 97(8):1869-75. PubMed ID: 12673712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.